These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
134 related articles for article (PubMed ID: 28975182)
41. Targeted radionuclide therapy for neuroendocrine tumours: principles and application. Druce MR; Lewington V; Grossman AB Neuroendocrinology; 2010; 91(1):1-15. PubMed ID: 19590162 [TBL] [Abstract][Full Text] [Related]
42. Radiopeptide imaging and therapy in Europe. Ambrosini V; Fani M; Fanti S; Forrer F; Maecke HR J Nucl Med; 2011 Dec; 52 Suppl 2():42S-55S. PubMed ID: 22144555 [TBL] [Abstract][Full Text] [Related]
43. Radiolabelled peptides for tumour therapy: current status and future directions. Plenary lecture at the EANM 2002. de Jong M; Kwekkeboom D; Valkema R; Krenning EP Eur J Nucl Med Mol Imaging; 2003 Mar; 30(3):463-9. PubMed ID: 12569416 [TBL] [Abstract][Full Text] [Related]
44. Targeted systemic radiotherapy of pheochromocytoma and medullary thyroid cancer. Divgi C Semin Nucl Med; 2011 Sep; 41(5):369-73. PubMed ID: 21803187 [TBL] [Abstract][Full Text] [Related]
46. Advances in radiation oncology. Elshaikh M; Ljungman M; Ten Haken R; Lichter AS Annu Rev Med; 2006; 57():19-31. PubMed ID: 16409134 [TBL] [Abstract][Full Text] [Related]
47. Proliferation and the advantage of longer-lived radionuclides in radioimmunotherapy. Howell RW; Goddu SM; Rao DV Med Phys; 1998 Jan; 25(1):37-42. PubMed ID: 9472824 [TBL] [Abstract][Full Text] [Related]
48. Radionuclide therapy of tumors: general aspects and considerations. Hoefnagel CA Int J Biol Markers; 1993; 8(3):172-9. PubMed ID: 8277209 [TBL] [Abstract][Full Text] [Related]
49. [Radionuclide therapy of malignant tumors]. Altenbrunn HJ Z Gesamte Inn Med; 1978 Jul; 33(14):475-84. PubMed ID: 581247 [TBL] [Abstract][Full Text] [Related]
50. [Radionuclide therapy--a possible way toward an improved treatment of cancer. The obstacle is the shortage of commercially available radionuclides for clinical use]. Lundqvist H; Carlsson J; Gedda L; Tolmachev V; Garske U; Kairemo K Lakartidningen; 2004 Mar; 101(11):1000-2, 1005-6. PubMed ID: 15055121 [TBL] [Abstract][Full Text] [Related]
51. Radionuclide Therapies in Molecular Imaging and Precision Medicine. Kendi AT; Moncayo VM; Nye JA; Galt JR; Halkar R; Schuster DM PET Clin; 2017 Jan; 12(1):93-103. PubMed ID: 27863570 [TBL] [Abstract][Full Text] [Related]
52. Therapeutic schemes in 177Lu and 90Y-PRRT: radiobiological considerations. Sarnelli A; Guerriero F; Botta F; Ferrari M; Strigari L; Bodei L; D'Errico V; Grassi E; Fioroni F; Paganelli G; Orecchia R; Cremonesi M Q J Nucl Med Mol Imaging; 2017 Jun; 61(2):216-231. PubMed ID: 26576734 [TBL] [Abstract][Full Text] [Related]
57. Criteria for the selection of radionuclides for targeting nuclear antigens for cancer radioimmunotherapy. Srivastava SC Cancer Biother Radiopharm; 1996 Feb; 11(1):43-50. PubMed ID: 10851519 [TBL] [Abstract][Full Text] [Related]
58. An analytic dosimetry study for the use of radionuclide-liposome conjugates in internal radiotherapy. Emfietzoglou D; Kostarelos K; Sgouros G J Nucl Med; 2001 Mar; 42(3):499-504. PubMed ID: 11337529 [TBL] [Abstract][Full Text] [Related]
59. Radiopharmaceuticals in the elderly cancer patient: Practical considerations, with a focus on prostate cancer therapy: A position paper from the International Society of Geriatric Oncology Task Force. Prior JO; Gillessen S; Wirth M; Dale W; Aapro M; Oyen WJG Eur J Cancer; 2017 May; 77():127-139. PubMed ID: 28391026 [TBL] [Abstract][Full Text] [Related]